Efficacy and Safety of Regdanvimab (CT-P59): A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial in Outpatients with Mild-to-Moderate Coronavirus Disease 2019
Streinu-Cercel et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofac053
https://c19early.org/streinucercel.html